Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel B Costa

Showing results (71-80 of 175) with videos related to

Pageof 18
Sort By:
Lung Cancer (Amsterdam, Netherlands)|January 1, 2013
Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutationsElizabeth M Gaughan, Sarah K Cryer, Beow Y Yeap, et al.
JTO Clinical and Research Reports|November 23, 2020
Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by <i>MET</i>-D1228 and <i>MET</i>-Y1230 Mutations in <i>EGFR</i>-Mutated <i>MET</i>-Amplified Lung CancerAndrew J Piper-Vallillo, Brian T Halbert, Deepa Rangachari, et al.
Clinical Lung Cancer|April 6, 2017
Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center AnalysisMarcello DiStasio, Yigu Chen, Deepa Rangachari, et al.
Clinical Lung Cancer|May 26, 2018
Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving TargetPaul A VanderLaan, Yigu Chen, Marcello DiStasio, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 21, 2025
A Comprehensive Mutational and Histopathological Analysis of STK11-Mutant Non-Small Cell Lung CarcinomasCristiana M Pineda, Zoe Guan, Hyunwoo Kwon, et al.
Journal of the American Society of Cytopathology|May 2, 2018
PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?Vanda F Torous, Deepa Rangachari, Benjamin P Gallant, et al.
Cancer Treatment and Research Communications|September 13, 2018
Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitisMeghan Shea, Deepa Rangachari, Robert W Hallowell, et al.
Precision Cancer Medicine|August 11, 2020
Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?Kartik Sehgal, Andrew J Piper-Vallillo, Hollis Viray, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 9, 2018
Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung CancerKartik Sehgal, Mary Linton B Peters, Paul A VanderLaan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 21, 2017
Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung AdenocarcinomaDeepa Rangachari, Paul A VanderLaan, Meghan Shea, et al.
Pageof 18

Showing results (71-80 of 175) with videos related to

Sort By:
Pageof 18
Lung Cancer (Amsterdam, Netherlands)|January 1, 2013
Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutationsElizabeth M Gaughan, Sarah K Cryer, Beow Y Yeap, et al.
JTO Clinical and Research Reports|November 23, 2020
Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by <i>MET</i>-D1228 and <i>MET</i>-Y1230 Mutations in <i>EGFR</i>-Mutated <i>MET</i>-Amplified Lung CancerAndrew J Piper-Vallillo, Brian T Halbert, Deepa Rangachari, et al.
Clinical Lung Cancer|April 6, 2017
Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center AnalysisMarcello DiStasio, Yigu Chen, Deepa Rangachari, et al.
Clinical Lung Cancer|May 26, 2018
Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving TargetPaul A VanderLaan, Yigu Chen, Marcello DiStasio, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 21, 2025
A Comprehensive Mutational and Histopathological Analysis of STK11-Mutant Non-Small Cell Lung CarcinomasCristiana M Pineda, Zoe Guan, Hyunwoo Kwon, et al.
Journal of the American Society of Cytopathology|May 2, 2018
PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?Vanda F Torous, Deepa Rangachari, Benjamin P Gallant, et al.
Cancer Treatment and Research Communications|September 13, 2018
Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitisMeghan Shea, Deepa Rangachari, Robert W Hallowell, et al.
Precision Cancer Medicine|August 11, 2020
Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?Kartik Sehgal, Andrew J Piper-Vallillo, Hollis Viray, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 9, 2018
Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung CancerKartik Sehgal, Mary Linton B Peters, Paul A VanderLaan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 21, 2017
Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung AdenocarcinomaDeepa Rangachari, Paul A VanderLaan, Meghan Shea, et al.
Pageof 18